Respiratory System Neoplasm

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 F82L was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 F… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 M90I was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 M… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in approx. 2% of lung adenocarcinomas (5/87 in the "oncogene negative" samples of TCGA - no RIT1 mutations were observed in 143 samples with a known driver mutation). GD… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

This study contained 230 patients with untreated lung adenocarcinoma. Whole-exome sequencing of tumor cells yielded that RTK/RAS/RAF based mutations to be 62%. However, analysis shows that NF1 mutatio… (full text at CIViC)

PMID 25079552 · 2014, Nature · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 Q40L was expressed in NIH3T3 cells and did not induce colony formation in soft agar greater tha… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 Q79L, a known activating mutation, was expressed in NIH3T3 cells and induced colony formation i… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

A patient with ROS1 fusion-positive NSCLC was treated with crizotinib for 26 months led to response (-64%). After tumor progression, a rebiopsy sample was obtained and revealed ROS1 D2033N mutation. S… (full text at CIViC)

PMID 26673800 · Drilon et al., 2016 · Open in CIViC

In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC)

PMID 29333528 · Gainor et al., 2017 · Open in CIViC

In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC)

PMID 29333528 · Gainor et al., 2017 · Open in CIViC

Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistan… (full text at CIViC)

PMID 23724914 · Awad et al., 2013 · Open in CIViC

Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival o… (full text at CIViC)

PMID 25351743 · Katayama et al., 2015 · Open in CIViC

Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. An acquired G2032R mut… (full text at CIViC)

PMID 23724914 · Awad et al., 2013 · Open in CIViC

In preclinical models, DS-6051b inhibited tumour growth and phospho-ROS1 levels in CD74-ROS1 G2032R mutant Ba/F3 cells. Similar results were seen in the crizotinib-resistant patient derived MGH047-4 c… (full text at CIViC)

PMID 31399568 · Katayama et al., 2019 · Open in CIViC

Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M muta… (full text at CIViC)

PMID 25733882 · Zou et al., 2015 · Open in CIViC

In a phase 1-2 trial (NCT03093116), the ROS1/ALK/NTRK inhibitor repotrectinib demonstrated efficacy in NSCLC with ROS1 fusions. In the 56 patients who had previously received one ROS1 tyrosine kinase… (full text at CIViC)

PMID 38197815 · Drilon et al., 2024 · Open in CIViC

Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib.

PMID 25688157 · Song et al., 2015 · Open in CIViC

Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib.

PMID 25688157 · Song et al., 2015 · Open in CIViC

Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cel… (full text at CIViC)

PMID 25733882 · Zou et al., 2015 · Open in CIViC

Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74–ROS1; however, showed similar sensitivity t… (full text at CIViC)

PMID 25688157 · Song et al., 2015 · Open in CIViC

The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2–ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib … (full text at CIViC)

PMID 25688157 · Song et al., 2015 · Open in CIViC

A patient with ROS1 fusion-positive NSCLC was treated with crizotinib for 26 months achieved tumor response (-64%). After tumor progression, a rebiopsy sample was obtained and revealed ROS1 R2033N mut… (full text at CIViC)

PMID 26673800 · Drilon et al., 2016 · Open in CIViC

Study describes the expansion of a phase 1 study of crizotinib in a 50 patient cohort with advanced NSCLC and exhibiting ROS1 rearrangements. Among the 50 patients 72% exhibited a response (3 complete… (full text at CIViC)

PMID 25264305 · Shaw et al., 2014 · Open in CIViC

In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC)

PMID 29333528 · Gainor et al., 2017 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing S1986F mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 116 nM), as compared… (full text at CIViC)

PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing a S1986Y mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 125 nM), as compar… (full text at CIViC)

PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC

A patient with ROS1 fusion-positive NSCLC was treated with crizotinib and led to durable response (-75%) over 22 months. After tumor progression, a rebiopsy sample was obtained and revealed ROS1 S1986… (full text at CIViC)

PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC

Expression level of RRM1 was evaluated in 61 NSCLC samples with RT-qPCR. Low expression of RRM1 was associated with longer median survival time (13.9 versus 10.9 months, P = 0.039). However, RRM1 expr… (full text at CIViC)

PMID 16980606 · Ceppi et al., 2006 · Open in CIViC

In this study, 229 tumors were analyzed for RRM1 expression. This resulted in 146 that were negative for RRM1 expression and 83 that were positive. These tumors were studied for a relationship between… (full text at CIViC)

PMID 24647522 · Dong et al., 2014 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with SCN8A deleterious Q427* mutation, treated with pembrolizumab monotherapy, was associated with a d… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In patient with lung adenocarcinoma an SDC4-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the detected gene fusion, prioritizin… (full text at CIViC)

PMID 28950338 · Jones et al., 2017 · Open in CIViC